The project, called the COVID-19 Diagnostics Evidence Accelerator, aims to examine COVID-19 data to shape better testing strategies and improve understanding of the disease’s spread. It is focusing on whether antibodies indicate immunity and which ones guard against infection.
“The Diagnostics Evidence Accelerator will allow the community to analyze both diagnostic and clinical data in real time, which has the potential to contribute to the scientific evaluation of diagnostic tools and medical interventions for COVID-19,” Amy Abernethy, MD, PhD, the FDA’s principal deputy commissioner, said in a June 18 news release.
More articles on data analytics:
Microsoft uses undersea data center in search of COVID-19 vaccine
Cleveland Clinic receives $7.2M NIH grant to study MS diagnostics
NIH launches COVID-19 tracking initiatives through ‘All of Us’ precision medicine program
